A Phase 3 interventional study of Belantamab mafodotin and Pomalidomide in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 122 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 5th largest by enrollment, is one of 6 that started in 2020, is one of 9 in phase 3, reaches primary completion later than 2 of the 34 other live ones, and was the 11th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
PrECOG, LLC. · Sites in United States
Ages 18–79
GlaxoSmithKline · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 29 · Phase 3 9
First in 2014; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 49 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 49 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
42 studies in Multiple Myeloma by GlaxoSmithKline: 6 open now, 20 under way, 7 of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 5th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2020, is one of 8 in phase 3, reaches primary completion later than 2 of the 19 other live ones, and was the 24th registered.
GlaxoSmithKline’s Multiple Myeloma studies by the year they started, since 2006.
4 of the studies testing belantamab mafodotin in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT03715478Canadian Myeloma Research GroupMulti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | 2027-06-01 |
| NCT05556798Memorial Sloan Kettering Cancer CenterA Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | 2027-10 |
| NCT05208307Emory UniversityBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | 2027-10-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, from their registry updates:
Among GlaxoSmithKline’s 42 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have at least 1 aspect of defined as one of the following;
Exclusion Criteria:
Evidence of cardiovascular risk including any of the following;
Previous or concurrent invasive other than multiple myeloma, except:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Belantamab mafodotin · Drug: Pomalidomide · Drug: Dexamethasone
Drug: Pomalidomide · Drug: Dexamethasone · Drug: Bortezomib
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
Immunomodulatory drug (IMiD) will be administered.
Synthetic glucocorticoid with anti-tumor activity will be administered.
Proteasome Inhibitor will be administered.
Progression-Free Survival (PFS)
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD is defined as increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.
Time frame: Up to approximately 174 weeks
Overall Survival (OS)
Overall Survival (OS) defined as the interval of time from randomization to the date of death due to any cause.
Time frame: Up to approximately 473 weeks
Duration of Response (DoR)
Duration of Response (DoR) defined as the time from first documented evidence of PR or better until progressive disease (PD) or death due to any cause. Response will be based on IRC-assessment per IMWG criteria.
Time frame: Up to approximately 473 weeks
Minimal Residual Disease (MRD) Negativity Rate
MRD negativity rate defined as the percentage of participants who achieve MRD negative status (as assessed by next-generation sequencing at 10\^5 threshold) at least once during the time of confirmed CR or better response based on IRC-assessment per IMWG.
Time frame: Up to approximately 473 weeks
Overall Response Rate (ORR)
ORR will be defined as the percentage of participants with a confirmed partial response or better (i.e., PR, VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.
Time frame: Up to approximately 473 weeks
Complete Response Rate (CRR)
Complete Response Rate (CRR), defined as the percentage of participants with a confirmed complete response (CR) or better (i.e., CR and stringent complete response (sCR)) based on IRC assessment per IMWG criteria.
Time frame: Up to approximately 473 weeks
Percentage of Participants With a Confirmed Very Good Partial Response (VGPR) or Better
VGPR is defined as the percentage of participants with a confirmed VGPR or better (i.e., VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.
Time frame: Up to approximately 473 weeks
Time to Best Response (TTBR)
TTBR defined as the interval of time between the date of randomization and the earliest date of achieving best response among participants with a confirmed PR or better based on IRC-assessment per IMWG.
Time frame: Up to approximately 473 weeks
Time to Response (TTR)
TTR defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve a response (i.e., confirmed PR or better) based on IRC-assessment per IMWG.
Time frame: Up to approximately 473 weeks
Time to Progression (TTP)
TTP defined as the time from randomization until the earliest date of PD based on IRC-assessment per IMWG criteria, or death due to PD.
Time frame: Up to approximately 473 weeks
Progression-Free Survival 2 (PFS2)
PFS2 defined as time from randomization to disease progression (investigator-assessed response) after initiation of new anti-myeloma therapy or death from any cause, whichever is earlier. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.
Time frame: Up to approximately 473 weeks
Number of Participants With Adverse Events (AEs)
Time frame: Up to approximately 473 weeks
Number of Participants With Clinically Significant Changes in Hematology Parameters
Blood samples will be collected for the analysis of hematology parameters.
Time frame: Up to approximately 473 weeks
Number of Participants With Clinically Significant Changes in Clinical Chemistry Parameters
Blood samples will be collected for the analysis of clinical chemistry parameters.
Time frame: Up to approximately 473 weeks
Number of Participants With Abnormal Ocular Findings on Ophthalmic Examination
Time frame: Up to approximately 473 weeks
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Blood samples will be collected for PK analysis of belantamab mafodotin.
Time frame: Up to approximately 473 weeks
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Blood samples will be collected for PK analysis of belantamab mafodotin.
Time frame: Up to approximately 473 weeks
Area Under Plasma Concentration-time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (C(Tlast)) [AUC (0-last)] for Pomalidomide
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Time frame: Up to approximately 473 weeks
Area Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Pomalidomide
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Time frame: Up to approximately 473 weeks
Maximum Concentration (Cmax) for Pomalidomide
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Time frame: Up to approximately 473 weeks
Time of Cmax (Tmax) for Pomalidomide
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Time frame: Up to approximately 473 weeks
Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Pomalidomide
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Time frame: Up to approximately 473 weeks
Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Pomalidomide
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Time frame: Up to approximately 473 weeks
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.
Time frame: Up to approximately 473 weeks
Titers of ADAs Against Belantamab Mafodotin
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further characterized for antibody titers.
Time frame: Up to approximately 473 weeks
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.
Time frame: Up to approximately 473 weeks
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These includes five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores are averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represents better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represents significant symptomatology. Baseline is defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline is calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Up to approximately 473 weeks
Change From Baseline in Quality of Life Questionnaire 20-item Multiple Myeloma Module (QLQMY20)
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score for Future Perspective and Body Image represents a high/healthy level of functioning.
Time frame: Up to approximately 473 weeks
Change From Baseline in HRQoL as Measured by EORTC IL52
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score for Future Perspective and Body Image represents a high/healthy level of functioning.
Time frame: Up to approximately 473 weeks
| Milestone | Belantamab Mafodotin+Pomalidomide+Dexamethasone | Pomalidomide+Bortezomib+Dexamethasone |
|---|---|---|
| Started | 155 | 147 |
| Safety population | 150 | 145 |
| Completed | 48 | 54 |
| Not completed | 107 | 93 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 8 |
| Withdrew: Ongoing | 94 | 84 |
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD is defined as increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.
| Months | Belantamab Mafodotin+Pomalidomide+Dexamethasone | Pomalidomide+Bortezomib+Dexamethasone |
|---|---|---|
| Progression-Free Survival (PFS) | NA (20.6 to NA) | 12.7 (9.1 to 18.5) |
Overall Survival (OS) defined as the interval of time from randomization to the date of death due to any cause.
Results for this outcome have not been posted.
Duration of Response (DoR) defined as the time from first documented evidence of PR or better until progressive disease (PD) or death due to any cause. Response will be based on IRC-assessment per IMWG criteria.
Results for this outcome have not been posted.
MRD negativity rate defined as the percentage of participants who achieve MRD negative status (as assessed by next-generation sequencing at 10\^5 threshold) at least once during the time of confirmed CR or better response based on IRC-assessment per IMWG.
Results for this outcome have not been posted.
ORR will be defined as the percentage of participants with a confirmed partial response or better (i.e., PR, VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.
Results for this outcome have not been posted.
Complete Response Rate (CRR), defined as the percentage of participants with a confirmed complete response (CR) or better (i.e., CR and stringent complete response (sCR)) based on IRC assessment per IMWG criteria.
Results for this outcome have not been posted.
VGPR is defined as the percentage of participants with a confirmed VGPR or better (i.e., VGPR, CR, and sCR) based on IRC-assessment per IMWG criteria.
Results for this outcome have not been posted.
TTBR defined as the interval of time between the date of randomization and the earliest date of achieving best response among participants with a confirmed PR or better based on IRC-assessment per IMWG.
Results for this outcome have not been posted.
TTR defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve a response (i.e., confirmed PR or better) based on IRC-assessment per IMWG.
Results for this outcome have not been posted.
TTP defined as the time from randomization until the earliest date of PD based on IRC-assessment per IMWG criteria, or death due to PD.
Results for this outcome have not been posted.
PFS2 defined as time from randomization to disease progression (investigator-assessed response) after initiation of new anti-myeloma therapy or death from any cause, whichever is earlier. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Blood samples will be collected for the analysis of hematology parameters.
Results for this outcome have not been posted.
Blood samples will be collected for the analysis of clinical chemistry parameters.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Blood samples will be collected for PK analysis of belantamab mafodotin.
Results for this outcome have not been posted.
Blood samples will be collected for PK analysis of belantamab mafodotin.
Results for this outcome have not been posted.
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Results for this outcome have not been posted.
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Results for this outcome have not been posted.
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Results for this outcome have not been posted.
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Results for this outcome have not been posted.
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Results for this outcome have not been posted.
Blood samples will be collected for PK analysis of Pomalidomide in combination with belantamab mafodotin and dexamethasone.
Results for this outcome have not been posted.
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.
Results for this outcome have not been posted.
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further characterized for antibody titers.
Results for this outcome have not been posted.
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.
Results for this outcome have not been posted.
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These includes five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores are averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represents better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represents significant symptomatology. Baseline is defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline is calculated by subtracting Baseline value from the post-dose visit value.
Results for this outcome have not been posted.
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score for Future Perspective and Body Image represents a high/healthy level of functioning.
Results for this outcome have not been posted.
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score for Future Perspective and Body Image represents a high/healthy level of functioning.
Results for this outcome have not been posted.
Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to approximately 174 weeks. The results presented are until the primary completion date. Additional results will be provided within a year of study completion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belantamab Mafodotin+Pomalidomide+Dexamethasone | 48/155 (31%) | 95/150 (63.3%) | 148/150 (98.7%) |
| Pomalidomide+Bortezomib+Dexamethasone | 54/147 (36.7%) | 65/145 (44.8%) | 130/145 (89.7%) |
| Event | Belantamab Mafodotin+Pomalidomide+Dexamethasone | Pomalidomide+Bortezomib+Dexamethasone |
|---|---|---|
| PneumoniaInfections and infestations | 27/150 | 11/145 |
| COVID-19 pneumoniaInfections and infestations | 17/150 | 6/145 |
| COVID-19Infections and infestations | 10/150 | 4/145 |
| NeutropeniaBlood and lymphatic system disorders | 9/150 | 4/145 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/150 | 5/145 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/150 | 3/145 |
| Urinary tract infectionInfections and infestations | 5/150 | 0/145 |
| Acute kidney injuryRenal and urinary disorders | 3/150 | 4/145 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/150 | 4/145 |
| Atrial fibrillationCardiac disorders | 1/150 | 3/145 |
| Event | Belantamab Mafodotin+Pomalidomide+Dexamethasone | Pomalidomide+Bortezomib+Dexamethasone |
|---|---|---|
| Vision blurredEye disorders | 119/150 | 22/145 |
| Dry eyeEye disorders | 91/150 | 14/145 |
| Foreign body sensation in eyesEye disorders | 91/150 | 9/145 |
| Eye irritationEye disorders | 75/150 | 13/145 |
| NeutropeniaBlood and lymphatic system disorders | 69/150 | 48/145 |
| PhotophobiaEye disorders | 66/150 | 6/145 |
| ThrombocytopeniaBlood and lymphatic system disorders | 54/150 | 40/145 |
| Eye painEye disorders | 49/150 | 7/145 |
| COVID-19Infections and infestations | 48/150 | 27/145 |
| CataractEye disorders | 40/150 | 14/145 |
| Age, Continuous(YEARS) | Belantamab Mafodotin+Pomalidomide+Dexamethasone | Pomalidomide+Bortezomib+Dexamethasone | Total |
|---|---|---|---|
| Mean | 65.5 ± 8.56 | 66.7 ± 10.03 | 66.1 ± 9.31 |
| Sex: Female, Male(Participants) | Belantamab Mafodotin+Pomalidomide+Dexamethasone | Pomalidomide+Bortezomib+Dexamethasone | Total |
|---|---|---|---|
| Female | 56 | 65 | 121 |
| Male | 99 | 82 | 181 |
| Race/Ethnicity, Customized(Participants) | Belantamab Mafodotin+Pomalidomide+Dexamethasone | Pomalidomide+Bortezomib+Dexamethasone | Total |
|---|---|---|---|
| White | 133 | 127 | 260 |
| Others | 22 | 20 | 42 |
Showing the first 100 of 122 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Ran from Oct 2020 to primary completion in Jan 2024, 39 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 39 months is below that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belantamab mafodotin